CABA (Cabaletta Bio) EPS (Basic) : $-2.16 (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cabaletta Bio EPS (Basic)?

Cabaletta Bio's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.62. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.16.

Cabaletta Bio's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.62. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.16.

Cabaletta Bio's EPS without NRI for the three months ended in Sep. 2024 was $-0.62. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -2.16.

During the past 3 years, the average EPS without NRI Growth Rate was -4.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Cabaletta Bio's highest 3-Year average EPS without NRI Growth Rate was 23.70% per year. The lowest was -28.90% per year. And the median was -4.60% per year.

Cabaletta Bio EPS (Basic) Historical Data

The historical data trend for Cabaletta Bio's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabaletta Bio EPS (Basic) Chart

Cabaletta Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-4.07

-1.44

-1.80

-1.81

-1.65

Cabaletta Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.37	-0.47	-0.51	-0.56	-0.62

Cabaletta Bio EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cabaletta Bio's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-67.675	-	0)	/	39.192
	=	-1.73

Cabaletta Bio's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-30.629	-	0)	/	49.471
	=	-0.62

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16

Cabaletta Bio (NAS:CABA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cabaletta Bio EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cabaletta Bio's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabaletta Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabaletta Bio Inc (NAS:CABA) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104

Website

https://www.cabalettabio.com

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Executives

Gwendolyn Binder	officer: EVP, Science & Technology	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Steven Nichtberger	director, officer: President & CEO	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Catherine Bollard	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Anup Marda	officer: Chief Financial Officer	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Mark Simon	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arun Das	officer: Chief Business Officer	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Michael Gerard	officer: General Counsel	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Brian Daniels	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543